Autopsy report · NCT01471197

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

“Administrative reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 7 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Bristol-Myers Squibb

Sponsor type

Industry

Conditions

Lung Cancer - Non Small Cell

Interventions

Ipilimumab; Pemetrexed

Participants

9

Sites

13

Countries

Belgium, France, Germany, Spain, United States

Trials that died the same way

• An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
  “Administrative Reason” (94% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (77% match in meaning)
• Clinical and Cost Effectiveness of Different Dressing Materials in Diabetic Foot Ulcers
  “Due to administrative reason” (73% match in meaning)
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
  “Business reasons” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.